Ultrasound-guided hydrodissection outlasts steroid injections in carpal tunnel syndrome
A 15-minute office procedure may change how clinicians approach carpal tunnel syndrome when splints, pain medicines, and prior injections no longer provide durable relief. In a randomized trial of 63 patients, ultrasound-guided hydrodissection with ordinary saline produced longer-lasting improvement in pain, numbness, and hand function than a standard corticosteroid injection, and it did so without added steroid exposure.
The practical appeal is obvious at the bedside. Carpal tunnel syndrome compresses the median nerve as it traverses the wrist’s narrow tunnel, and when that pressure persists, symptoms can extend far beyond nighttime tingling. Patients often describe dropping objects, waking with burning hands, or losing fine motor control in daily tasks. A treatment that mechanically frees the nerve rather than simply quieting inflammation fits the underlying problem more closely than medication alone.
Mechanical decompression, not just anti-inflammatory therapy
Hydrodissection uses real-time ultrasound to place fluid around the compressed nerve and separate it from adjacent tissue planes. In theory, that loosens adhesions, restores nerve glide, and reduces the local crowding that perpetuates symptoms. Steroid injections can blunt inflammation and provide temporary relief, but they do not necessarily address the physical tethering around the median nerve. The trial’s results suggest that this difference matters over time.
Investigators enrolled patients with confirmed carpal tunnel syndrome whose symptoms had persisted despite conventional management. The cohort was divided into three groups: saline hydrodissection alone, hydrodissection with saline plus corticosteroid, and ultrasound-guided corticosteroid injection without hydrodissection. Follow-up assessments occurred at four, 12, and 24 weeks using standardized measures of pain, symptom severity, and hand function, along with ultrasound measurements of median nerve size.
Early gains were shared, but durability separated the groups
At four weeks, all three treatment arms improved. The split emerged later.
By 12 weeks and six months, both hydrodissection groups continued to improve clinically, while patients who received corticosteroid injection alone began to show recurrent symptoms. That pattern is exactly what clinicians see when a therapy calms a compressed nerve without changing the mechanical environment around it: initial relief comes quickly, then fades as the same anatomic pressure returns.
The trial also found no statistically significant long-term advantage from adding corticosteroid to the hydrodissection fluid. Saline alone performed just as well over the six-month follow-up window. For clinicians, that finding matters because it suggests a simpler, steroid-free procedure may deliver the same sustained benefit without exposing patients to steroid-related adverse effects.
Ultrasound confirmed a larger anatomical response
The imaging data reinforced the symptom findings. In the hydrodissection groups, the median nerve cross-sectional area fell by roughly 43% to 45%. In the corticosteroid-only group, the reduction was about 15%.
That discrepancy points to a structural effect rather than a transient analgesic one. A smaller nerve caliber on ultrasound implies less swelling and less compression inside the carpal tunnel, which offers a plausible explanation for the longer-lived clinical benefit. When the nerve can move more freely and the surrounding tissue planes are separated, repetitive friction and pressure likely decline as well. The result is a treatment that addresses both symptoms and anatomy.
A short procedure with a low burden for patients
The procedure itself averaged about 15 minutes, was generally well tolerated, and produced no significant complications during or after treatment. Patients did not require anesthesia or hospitalization, and they returned to work within an hour. Those details are not trivial for a condition that often affects working adults who need fast recovery and minimal disruption.
Cost and accessibility also favor the approach. A saline-based ultrasound-guided procedure avoids repeated steroid exposure, may reduce the need for serial injections, and could help postpone surgery in selected patients. In a condition as common as carpal tunnel syndrome, even modest reductions in surgical referrals would have meaningful implications for patients and clinics.
The patient perspective was favorable as well. Many participants had already endured symptoms for months to years and had tried pain medicines, splints, lifestyle changes, and corticosteroids without durable success. For that group, a procedure that produced sustained relief with a simple saline injection represents a clinically meaningful shift, not a marginal tweak.
What the six-month window can and cannot show
The trial’s strength lies in its randomized design and its combination of symptom scoring with ultrasound morphology. The limitation is just as clear: 63 patients is a small sample, and six months does not establish how long the benefit will last. Carpal tunnel syndrome often follows a chronic course, so durability beyond the first half-year remains the key question before broader adoption.
The investigators have already started a separate study comparing different hydrodissection fluids, including saline and dextrose. That next step should help define whether the benefit comes from the mechanical separation itself, the choice of injectate, or both. For now, the present trial supports a narrower conclusion: in refractory carpal tunnel syndrome, ultrasound-guided saline hydrodissection can outperform steroid injection alone over six months and may offer a credible way to delay or avoid surgery.
Surgical referral is not disappearing from the carpal tunnel pathway. But this trial gives clinicians a less invasive option that appears to match the anatomy of the disease more closely than steroid injection alone.